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Mitochondrial malic enzyme 2 (ME2) catalyzes the oxidative decarboxylation of malate to yield CO2 and
pyruvate, with concomitant reduction of dinucleotide cofactor NAD
1 or NADP
1. We find that ME2 is
highly expressed in many solid tumors. In the A549 non-small cell lung cancer (NSCLC) cell line, ME2
depletion inhibits cell proliferation and induces cell death and differentiation, accompanied by increased
reactive oxygen species (ROS) and NADP
1/NADPH ratio, a drop in ATP, and increased sensitivity to
cisplatin. ME2knockdownimpacts phosphoinositide-dependent proteinkinase 1(PDK1) and phosphatase
and tensin homolog (PTEN) expression, leading to AKT inhibition. Depletion of ME2 leads to malate
accumulation and pyruvate decrease, and exogenous cell permeable dimethyl-malate (DMM) mimics the
ME2 knockdown phenotype. Both ME2 knockdown and DMM treatment reduce A549 cell growth in vivo.
Collectively, our data suggest that ME2 is a potential target for cancer therapy.
L
ung cancer is the leading cause of cancer deaths
1 and approaches other than conventional chemotherapy or
radiation therapy are needed for prolonging survival of lung cancer patients. Approximately 75% of lung
cancer is non small cell lung cancer (NSCLC)
2. Mutations in EGFR, KRAS, LKB1 and PTEN, and over-
expression of MYC have been described
3,4. A549, a human adenocarcinoma NSCLC cell line
5,6 which is widely
usedforlungcancerstudies
7,8,carriesmutationsinLKB1
9andKRAS.Althoughthegeneisintact,thep53protein
is degraded in these cells due to deletion of the p14ARF locus
10. A549 cells have wild-type genes for epidermal
growth factor receptor EGFR, PTEN and MYC.
Malicenzymescatalyze the divalentmetal ion(Mn
21orMg
21) dependent oxidative decarboxylation of malate
to yield pyruvate and CO2, accompanied by the production of NADH or NADPH
11. Three isoforms have been
identified: cytosolic NADP
1-dependent (ME1), mitochondrial NAD(P)
1-dependent (ME2), and mitochondrial
NADP
1-dependent malic enzyme (ME3). ME2 responds to elevated amino acids and may supply pyruvate to
increaseTCAfluxwhenglucoseislimiting
12.ME2activityincreaseswithprogressiontoneoplasiainarattracheal
epithelial line
13 with similar findings in Morris hepatomas
14. The first functional connection between ME2
expression and cancer was recently published: knockdown of ME2 in K562 cells led to erythroid differentiation
in this model of chronic myelogenous leukemia
15.
Here, we have investigated the role of ME2 in lung cancer using A549 cells. Knockdown of ME2 induced cell
death and differentiation in vitro and impacted the PI3K/AKT/mTOR pathway. Supplementation of cell per-
meable dimethyl-malate (DMM) mimicked the phenotype caused by ME2 depletion. Moreover, depletion of
endogenous ME2 or administration of DMM inhibited tumor growth in vivo. These data suggest that ME2 may
be a potential target for lung cancer therapy.
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ME2 expression in lung tumor tissues. We hypothesized that ME2
might be overexpressed in clinical tumor samples. In eighty
specimens representing 13 types of solid tumors (Purchased from
Protein Biotechnologies, CA), ME2 protein was overexpressed in a
large number (Table S1, Figure S1). About 90% of lung tumors
overexpressed ME2 (Table S2 and Figure S2a and b). We
investigated ME2 expression in a human tumor tissue array from
US Biomax containing 8 types of solid tumors to assess ME2
expression in cancer versus normal tissue, and found that ME2 in
lung cancer significantly higher than normal tissue (Figure S2c and
Figure S3). Moreover, we also found that ME2 was overexpressed in
several othertumortypes(FigureS3). Inanother separate tissue array
containing 100 melanoma samples, we found that ME2 expression is
correlated to melanoma disease stage (Figure S4a). Similar data was
obtained with primary versus lymph node metastases in melanoma
(Figure S4b). These data suggest that ME2 may play a role in cancer
broadly and particularly in lung cancer.
ME2knockdownimpairsA549cellsproliferationandreprograms
metabolism.In A549 cells, all three constructs showed marked ME2
knockdown (Figure 1a), and knockdown of ME2 inhibited tumor
cells proliferation (Figure 1b) and colony formation (Figure 1g).
Similar results were obtained in three independent single clones
(Figure 1c and d), and one different lung cancer cell line: H1650 (a
lung cancer line resistant to TKI inhibition) (Figure 1e and f), as well
as MCF-7 cells (a breast cancer line) (Figure S2f and g), WM983B
(FigureS2handi)andWM852cells(melanomacelllines)(FigureS2j
and k).
To assess whether ME2 knockdown reprograms tumor cell meta-
bolism, we performed stable isotope-resolved metabolomics (SIRM)
studies by incubating ME2 knockdown or control cells in uniformly
13C enriched glucose (
13C6-Glc) or
13C/
15N enriched glutamine (
13C5,
15N2-Gln). ME2 knockdown cells showed a decrease in the
13C6-Glc-
derived fatty acyl chains (Figure 1h). The m(even) and m(odd . 3)
isotopologues represent intact phospholipids in which only the acyl
chains are enriched in
13C acetyl moieties and phospholipids where
both the fatty acyl chains and the glycerol backbone are enriched in
13C
16 as shown for the most abundant membrane lipids, phosphati-
dylcholine (PC) (Figure 1h). The decreased synthesis of the mem-
brane lipids is paralleled by reduced protein biosynthesis, as
evidenced by decreased consumption of essential amino acids such
as Val from the medium (Figure 1i), consistent with diminished cell
proliferation.
Survival of ME2 knockdown cells is exquisitely dependent on
glucose. Neither control nor ME2 knockdown cells could survive
in Hams/F12 medium in the absence of pyruvate, glucose and
Figure 1 | ME2 depletion inhibits proliferation. (a), Knockdown of ME2 in pools of A549 with three independent ME2 shRNA lentiviruses. The full-
length blots are presented in Supplemental Figure S7. (b), Cell proliferation with ME2 knockdown as described in ‘‘a’’. (c), ME2 knockdown in single
clones.Thefull-lengthblotsarepresentedinSupplementalFigureS8.(d),CellproliferationofsinglecloneswithME2knockdownasdescribedin‘‘c’’.(e),
KnockdownME2inH1650cells.Thefull-lengthblotsarepresented inSupplementalFigureS9.(f),Cellproliferation withME2knockdownasdescribed
in ‘‘e’’. (g), Knockdown of ME2 in A549 inhibits colony formation. (h), Fractional changes in
13C mass isotopologues (differing in the number of
13C
atoms) of phosphatidylcholines (PC) in ME2 knockdown cells; m0: all
12C, m3:
13C3-PC (
13C labeling in glycerol backbone only), m(even):
13Ceven#-PC
(
13C labeling in fatty acyl chains only), m(odd . 3):
13Codd#.3-PC (
13C labeling in fatty acyl chains plus glycerol backbone). (i), Time courses of valine
consumption, as determined from
1H NMR data. Metabolite data were expressed mean 6 SEM, n 5 2. (j), The effect of glutamine supplementation on
ME2 depletion induced cell death. (k), Pyruvate rescues ME2 knockdown induced cell death. (l) and (m), The effect of ME2 knockdown on de novo
synthesisofPCisgreaterwith
13C6-Glcthanwith
13C5,1
5N2-Glnastracer.(n),Inhibitionof
13C3-citratesynthesisfrom
13C6-GlcbyME2knockdown.(o),
13Catom-resolvedtracingfrom
13C6-Glcthroughglycolysis,theKrebscyclewithoutorwithinputofpyruvatecarboxylation,andbiosynthesisoffattyacyl
chains with even number of
13C(
13C2n) in lipids via citrate; respectively .,.:
13C atoms from the first turn of Krebs cycle without or with pyruvate
carboxylation; solid and dashed arrows: single and multiple-step reactions; single and double-headed arrows: irreversible and reversible reactions; PDH:
pyruvatedehydrogenase;PCB:pyruvatecarboxylase.(p)and(q),EffectsofME2knockdownonthelevelsandfractionaldistributionof
13Cisotopologues
ofmalate;redandgreenrectanglesdepict
13C2-(m2)and
13C3-malate(m3)speciesasmarkersofthefirstturnoftheKrebscyclewithoutandwithpyruvate
carboxylation input, respectively. Metabolite data were expressed mean 6 SEM, n 5 2.
www.nature.com/scientificreports
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control cells more than ME2 knockdown cells. Pyruvate supplemen-
tation rescued both ME2 knockdown and control cells (Figure 1k),
suggesting that pyruvate produced by ME2 from malate plays a pro-
survival role in A549 cells.
Why are ME2 knockdown cells sensitive to glucose deprivation?
SIRM studies showed that glucose is the preferred substrate for sup-
porting PC synthesis over glutamine (Figure 1l versus 1m). In addi-
tion, the attenuating effect of ME2 knockdown on PC synthesis
appearsto begreater with
13C6-Glcthan with
13C5,
15N2-Glnas tracer
(Figure 1l and m) and Gln cannot make glycerol in these cells.
Moreover, the glucose-mediated anaplerotic input into the Krebs
cycle via pyruvate carboxylation was attenuated in ME2 knockdown
cells, as evidenced by the reduced fractional distribution of triply
13C
labeled citrate (
13C3-citrate or m3 in Figure 1n), which is a unique
marker of pyruvate carboxylation (Figure 1o)
17,18. Citrate is regularly
diverted for fatty acid synthesis, which is in turn incorporated into
new phospholipids (PLs) (Figure 1o) required for cell proliferation
andmaintenance.Sincecitratereplenishmentfromglucoseisalready
reducedinME2knockdowncells,withholdingglucosewouldfurther
compromise their ability to maintain PL homeostasis, thereby cur-
tailing cell growth and survival.
DepletionofME2inducescelldeathanddifferentiation.Annexin-
V assays indicated that ME2 deficient tumor cells had much higher
ratesof cell death(9.4 to 11.7-fold) thancontrol cells (Figure 2a).On
the contrary, depletion of ME2 only slightly increased cell death in
normal lung primary epithelial cells (Figure S2d and e). Next, we
measured theexpression E-cadherin andZO-1,markersof epithelial
cell differentiation, in response to ME2 depletion. As shown in
Figure 2b, ME2 knockdown increased E-cadherin and ZO-1
expression in three independent pools. Thus, our data point to two
major effects of ME2 deficiency: increased differentiation as
exemplified by increases in E-cadherin and ZO-1 expression and a
decreased growth rate with cell death as the likely underlying
mechanism.
Depletion of ME2 inhibits ATP production, increases oxygen
consumption and enhances ROS production. We hypothesized
that increased cell death in ME2 deficient cells may reflect a drop
in ATP levels since ME2 plays a crucial role in glutamine oxidation
via the Krebs cycle
19. ME2 knockdown led to an approximately 50%
drop in ATP level (Figure 2c). A portion of this decrease in ATP
levels arose from a decrease in de novo ATP synthesis, as evidenced
from stable isotope tracer experiments coupled with FT-ICR-MS
analysis, where the total
13C fractional enrichment in ATP from
13C6-Glc tracer (at 50% supplement) was lower (42.6% 6 0.4%) for
ME2 deficient cells than for control cells (48.9% 6 0.8%).
Next, we asked whether this decrease reflects decreased ATP gen-
eration perhaps via a shift from mitochondrial oxidative phosphor-
ylation to fermentative glycolysis. We assessed O2 consumption and
extracellular acidification changes using a Seahorse bioanalyzer.
Contrary to our expectations, knockdown of ME2 led to a 3–4 fold
increase in oxygen consumption (Figure 2d), suggesting that ME2
depletion might be uncoupling ATP production from oxygen con-
sumption or activating ATP-consuming ‘‘futile’’ cycles with heat
production. The latter is unlikely since our data suggests that futile
cycles associated with pyruvate cycling in the mitochondrial are
Figure 2 | Knockdown of endogenous ME2 induces A549 cell death and differentiation, and inhibits ATP and NADPH production, while
enhancingA549cellsoxygenconsumptionandROSproduction.(a),DepletionofME2increasesA549basalcelldeath.(b),E-cadherin,ZO-1,ME2and
b-tubulin in A549 cells with or without ME2 knockdown were determined by Western blotting. The full-length blots are presented in Supplemental
Figure S10. Data are representative of two independent experiments. (c), Depletion of ME2 inhibits ATP production in A549 cells. Data are expressed as
mean6SD,n53.(d),Knockdown ofME2inA549 cellsincreases O2consumption. (e), Knockdown ofME2 inA549 cellsincreases [H
1]excretion. (f),
Increased
13C3-lactate excretion induced by ME2 knockdown in A549 cells, as determined by
1H NMR; data are expressed as mean 6 SEM, n 5 2. (g),
Increased ROS in A549 ME2 knockdown cells detected by flow cytometry using CM-H2DCFDA as probe. Each histogram is representative of three
experiments. (h), 5 mM exogenous NAC inhibits ME2 depletion-meditated ROS production. Each histogram is representative of two or three
experiments. (i), 5 mM NAC partially rescues ME2 knockdown induced cell death. Control groups without NAC treatment were normalized to100 and
NAC treated groups were compared to its control. Data are expressed as mean 6 SD, n 5 3. (j), Depletion of ME2 increases NADP/NADPH ratio. Data
are expressed as mean 6 SD, n 5 3.
www.nature.com/scientificreports
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also observed increased proton extrusion with ME2 knockdown
(Figure 2e), consistent with an increased rate of
13C3-lactate produc-
tion and release into the medium using
13C6-Glc as a tracer
(Figure2f).Clearly,ME2depletionleadstodramaticreprogramming
of intermediary metabolism.
We hypothesized that ME2 knockdown diminishes anti-oxidant
defenses, leading to increased ROS. Compared to empty vector con-
trol, we observed increases in basal ROS content in two independent
populations of ME2 knockdown cells, as quantified by flow cytome-
try using CD-H2DCFDA as a fluorescent probe (Figure 2g).
Exogenous N-acetylcysteine (NAC) inhibited ME2-mediated ROS
production (Figure 2h) and partially rescued cell death (Figure 2i).
The NADPH/NADP
1 ratio also decreased in ME2 knockdown cells
(Figure 2j). These data suggest that anti-oxidant defenses were com-
promised in ME2 depleted cells.
AKTsignalingisdownregulatedintheME2deficientstate.Meta-
bolites can signal to canonical molecular pathways
20. The increased
cell death and differentiation in ME2-depleted A549 cells suggested
that the PI3K/AKT or the RAS/RAF/MEK/ERK pathway might be
inhibited by ME2 knockdown. We first looked at the effects on basal
AKT phosphorylation using pAKT T308 and pAKT S473 specific
antibodies. Relative to control cells, phosphorylation at both T308
and S473 were markedly diminished in the ME2 deficient cells
(Figure 3a and b).
To further confirm the inhibition of AKT activity, we established
an inducible shRNA knockdown system. Doxycycline-induced ME2
depletionsignificantlyinhibitedAKTactivity(Figure3candd).ME2
deficiency down regulated phospho-AKT levels in response to EGF
stimulation (Figure 3e and f). Those data suggest again that ME2
regulates AKT signaling. Next, we examined molecular events
upstream of AKT activation, specifically PDK1 and PTEN. Deple-
tion of ME2 dramatically downregulated PDK1 and p-PDK1
expression (Figure 3e and f), suggesting that ME2 regulates AKT
activity via modulation of PDK1 levels. To test whether a parallel
pathway impinging on AKT is affected i.e. whether PTEN is
involved, we investigated PTEN and p-PTEN expression in both
ME2 knockdown and ME2 overexpressing cells. We found that
knockdown of ME2 increased PTEN and p-PTEN levels (Figure 3a),
whereas overexpression of ME2 in HEK 293 cells enhanced AKT
activation and decreased PTEN and p-PTEN expression (Figure 3g
and h). These data suggest that ME2 regulate AKT activity via modu-
lation of PTEN and PDK1 expression.
ROS are known activators of AMPK
21, and AMPK can activate
PTEN
22. Since depletion of ME2 leads to an increase in ROS, we
probed AMPK expression and activation in ME2 knockdown and
ME2overexpressingcells.KnockdownofME2increasedAMPKand
p-AMPK expression (Figure 3a). These results suggest that down
regulationofME2increasesROSlevels,leadingtoalteredexpression
levels of AMPK and PTEN, and consequent AKT activation.
Importantly, we found no change in pERK with ME2 knockdown
or overexpression, supporting the notion that ME2 expression is
unlikely to impact RAS activity, since RAS activation is known to
increase both ERK phosphorylation and AKT activity.
Supplementation by cell permeable exogenous dimethylmalate
(DMM) in A549 cells mimics the ME2 knockdown phenotype.
Since a function of ME2 is to convert mitochondrial malate into
pyruvate, it was not surprising to observe that knockdown of ME2
leads to malate accumulation (Figure 4a and b) as analyzed by two
different methods. This accumulation is mediated through reduced
ME2 activity, as evidenced by the accumulation of
13C2- and
13C3-
malate (m2 and m3 in Figure 1p) without changes in their fractional
enrichment (Figure 1q), which is consistent with a block in malate
catabolism via ME2.
13C2- and
13C3-malate is presumably derived
from
13C6-Glc via the sequence of glycolysis and the 1
st turn of the
Krebs cycle without or with input of pyruvate carboxylation,
respectively (Figure 1o)
17,23.
Next, we hypothesized that malate accumulation as a result of
reduced ME2 activity was responsible for the phenotype of ME2
knockdown cells. If this were true, exogenous malate might mimic
the phenotype-induced by ME2 knockdown. We supplemented the
cell culture medium with exogenous cell permeable malate in the
formofdimethylmalate(DMM)
24.ProliferationofA549-pLKOcells
was significantly inhibited with 10 and 20 mM DMM supplementa-
tion (Figure 4c and d). Also, ME2 depleted cells were more sensitive
toDMMtreatment (Figure 4c and d).Next, we assayedfor celldeath
using Annexin V expression. DMM treatment induced necrosis in
A549 control cells (Figure 4e), and ME2 knockdown cells were more
sensitive to DMM treatment. Consistent with enhanced ROS pro-
ductioninME2knockdownA549cells(Figure2g),exogenousDMM
treatment elicited a marked rise in ROS as detected by CM-
H2DCFDA (Figure 4f), suggesting that cell death-induced by
DMM treatment may be due to increased ROS. Also similar to what
was observed for ME2 depletion (Figure 3), 10 and 20 mM exogen-
ous DMM treatment diminished basal AKT and PDK1 activity and
increased E-cadherin expression in vitro (Figure 4g and h). These
data indicate that supplementation with a cell permeable form of
malate closely mimics the phenotype-induced by ME2 knockdown.
Antioxidants N-acetyl-cysteine (NAC) and glutathione (GSH)
rescue the phenotype induced by DMM treatment. Since DMM
largely mimicked the phenotype mediated by ME2 knockdown, we
testedwhetherinhibitingROSinDMM-treatedcellscouldrescuethe
cell death phenotype. We first measured mitochondrial ROS using
MitoSOXRedstaining.AsshowninFigure5a,whenA549cells were
treated with 20 mM DMM for 4 days, cells exhibited intense red
fluorescence indicative of superoxide production. DMM treatment
in the presence of 20 mM NAC led to complete inhibition of
superoxide production in the mitochondria. The DMM-induced
ROS production in A549 cells was time-dependent (Figure 5b, left
panel) as detected by CM-H2DCFDA fluorescence. Both exogenous
NACandGSHinhibitedDMM-induced ROS(Figure5bmiddleand
right panels). Importantly, NAC and GSH almost completely
inhibited cell death induced by 10 mM DMM (Figure 5c).
Furthermore, when cells were incubated with DMM and NAC or
GSH, there was reversal of differentiation induced by DMM
(Figure 5d). NAC or GSH treatment also restored DMM-inhibited
basal AKT activity (Figure 5d and f). Collectively, these data show
that exogenous NAC or GSH can rescue the phenotype-induced by
DMM treatment, suggesting that ROS play a pivotal role in this
phenotype.
We asked if DMM selectively kills tumor cells. Perhaps, it selec-
tivelyincreases ROSintumor versusnormalcells. Wefoundthisnot
to be case: DMM increased ROS levels in two normal cell lines
(Figure S5a). However, even though DMM triggered ROS increase
in both normal and tumor cells, DMM selectively killed tumor cells
(Figure S5b), suggesting that anti-oxidant defenses may be more
effective in non-tumor cells.
KnockdownofendogenousME2suppressestumorgrowthinvivo.
To study the effects of ME2 knockdown on the growth of A549 cells
in vivo, we injected vector control and ME2 knockdown clones
subcutaneously into nude mice and examined tumor formation
and progression. ME2 knockdown cells grew much slower than
wild type cells (Figure 6a). Western blotting confirmed knockdown
ofME2invivo(Figure6b).WealsoconstructedanshRNAinducible
system.Inonegroup(4mice),eachmousereceivedacontrol-shRNA
inoculationinoneflankandanME2shRNAcloneintheother.After
10 days, both control and ME2 shRNA tumors grew similarly. We
thenfedthemice2 mg/mlDoxplus15%sugar.After5weeks,tumor
sizes were measured. Similar to data obtained from the constitutive
shRNA knockdown, in the inducible system, knockdown of ME2
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5414 | DOI: 10.1038/srep05414 4also inhibited tumor growth as compared with control shRNA
(Figure 6c). Western blot confirmed ME2 knockdown in the
inducible system (Figure 6d).
CisplatiniscommonlyusedtotreatNSCLC.ItalsopromotesROS
production. To explore whether knockdown of ME2 may benefit
tumor therapy in the context of cisplatin treatment, we investigated
the effect of cisplatin on A549 cells with or without ME2 depletion.
Deficiency of ME2 in vitro increased the sensitivity of A549 cells in
vitro to cisplatin treatment (Figure 6e). We therefore treated A549
xenograft tumors formed from wild type and ME2 knockdown cells
with cisplatin. As shown in Figure 6f, ME2 depletion significantly
inhibited A549 tumor cell growth in vivo; however, the growth of
ME2 knockdown tumors resumed when the tumor size reached
about 350 mm
3. Cisplatin treatment could prevent this later tumor
growth. ME2 depletion inhibited mucin-1 and vimentin expression,
and increased tumor cell expression of E-cadherin and ZO-1 in vivo
(Figure6g).ThecombinationofME2depletionandcisplatinshowed
a particularly striking effect on E-cadherin and mucin-1 expression.
Finally, we tested the anti-tumor activity of DMM in vivo.
Administrationof0.5 g/kgDMMsignificantlyinhibitedA549tumor
growth (Figure S6a). A combination treatment of DMM and cispla-
tin showed even more marked effects on tumor growth. We also
tested the effect of DMM on tumor growth by directly injecting
DMM into A549 tumors: tumors shrank and ulcerated (Figure
Figure 3 | KnockdownofME2inhibitsAKTactivityinA549cells.(a),BasalAKT,PTENandAMPKlevelsandactivationinstableME2knockdowncells.
The full-length blots are presented in Supplemental Figure S11. (b), Quantitatively analysis p-Akt in ‘‘a’’ by densitometry assay. (c), Inducible shRNA
inducesME2knockdownandinhibitsbasalAKTactivityinA549cells.Thefull-lengthblotsarepresentedinSupplementalFigureS12.(d).Quantitatively
analysis p-Akt in ‘‘c’’ by densitometry assay. (e), A549 cell with or without ME2 knockdown were starved for 24 h, and stimulated with 100 ng/ml EGF.
The full-length blots are presented in Supplemental Figure S13. (f). Quantitatively analysis p-Akt in ‘‘e’’ by densitometry assay. (g), Overexpression of
human ME2 in HEK293 cells enhances AKT activation and decreases PTEN. For this figure, expression levels of ME2, p-AKT473, p-AKT308, AKT, p-
PDK1, PDK1, p-ERK1/2, ERK1/2, p-PTEN, PTEN, p-AMPK, AMPK and b-tubulin were determined by Western blotting. The full-length blots are
presented in Supplemental Figure S14. (h). Quantitatively analysis p-Akt in ‘‘g’’ by densitometry assay.
www.nature.com/scientificreports
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alsoinduced tumor celldifferentiation invivo,i.e.increased express-
ion of E-cadherin and ZO-1 (Figure S6c).
Discussion
This study extends our previous data on the role of ME2 in leukemic
cell differentiation
15 by supporting a role for ME2 in solid tumor
growth and differentiation and in lung cancer in particular. It also
definestheAKTpathwayasadownstreamtargetforME2actionand
points to a role for malate in explaining the ME2 knockdown
phenotype.
How does malate accumulation induce cell death and differenti-
ation? Since ME2 depletion causes malate accumulation in A549
cells, the accumulation of malate may enhance mitochondrial ROS
production.Indeed,cellstreatedwithacellpermeableformofmalate
showedinhibitionofcellproliferationandincreasedcelldeathwitha
concomitant increase in ROS, similar to the effects observed with
ME2 depletion. ROS play a crucial role in regulating cell growth,
differentiation and cell death. Cellular ROS levels are finely con-
trolled
25, since high levels of ROS can cause cell death, whereas low
levels of ROS can function as a second messenger. ROS can induce
celldifferentiationinhepatoma
26andleukemia
27.ROSproductionin
ME2 knockdown cells increased substantially, and increased ROS
production may mediate ME2 knockdown induced cell death and
differentiation. In support of this, the anti-oxidant NAC partially
rescued the phenotype. Since NAC rescue is presumably mediated
via regeneration of GSH, it is possible that the ME2 knockdown cells
areunabletoutilizeGSHforantioxidantdefenseas evidencedbythe
Figure 4 | Supplementationofexogenouscell-permeable DMMmimicstheME2deficientphenotype.(a),DepletionofME2inA549 cellscausemalate
accumulationanalyzedbyLC-MS.(b),MalateinME2knockdownandcontrolcellswereanalyzedbymalateassaykit.(c),TreatmentofA549controland
ME2 knockdown cells with DMM inhibits cell proliferation. (d), ME2 knockdown cells showed more sensitive to exogenous DMM treatment. (e),
Exogenous DMM treatment induces A549 control and ME2 knockdown cells undergoing necrosis. (f), Exogenous DMM treatment enhances ROS
production. Top: A549 cells treated with 20 mM DMM, and the ROS-induced by DMM were analyzed in different time as indicated; Bottom: ROS-
induced by different concentrations of DMM as indicated were analyzed. (g), Exogenous of DMM treatment induces A549 lung cancer cells
differentiation,andAKTandPDK1activityinhibition.Thefull-lengthblotsarepresentedinSupplementalFigureS15.(h),Quantitativelyanalysisp-Akt
in ‘‘g’’ by densitometry assay.
www.nature.com/scientificreports
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which may also explain why exogenous NAC could not completely
rescue the ME2 knockdown phenotype.
How might DMM treatment increase ROS levels? Mitochondrial
complexIplaysanimportantroleincontrollingROSgenerationand
malate is one of its substrates
28. Thus, malate accumulation in mito-
chondria may enhance the TCA cycle, accelerating ROS production.
AnotherwaytoincreaseROSlevelsistoinhibitantioxidantdefenses.
NADPH/NADP
1 is the principal redox couple involved in intracel-
lular ROS balance. Our data suggests that depletion of ME2 also
decreases NADPH/NADP
1 ratio (Figure 2j).
ME2 knockdown depletes a source of pyruvate production and
this inhibition may also partly contribute to cell growth inhibition.
ME2 knockdown cells loss the ability to use glutamine (Figure 1j),
Figure 5 | NAC and GSH rescue exogenous DMM induced phenotype in A549 lung cancers. (a), Accumulation of mitochondrially generated
superoxideinA549cellsasdetectedbyMitoSOX(Top:MitoSOXred;Bottom:Phasecontrast).Dataarerepresentativeoftwoindependentexperiments.
(b),NACandGSHinhibittheROSinducedbyexogenousDMMinA549cells.ROSinA549cellsdetectedbyflowcytometryusingCM-H2DCFDA.Each
histogram is representative of three experiments. Left: A549 cells were treated with 10 mM DMM with or without 20 mM NAC or 20 mM GSH. Right:
A549cellsweretreatedwith20 mMDMMwithorwithout20 mMNACor20 mMGSH.(c),NACorGSHinhibits10 mMDMMinducedcelldeath.(d),
NAC or GSH inhibits DMM induced cell differentiation and rescue the AKT inhibition. The full-length blots are presented in Supplemental Figure S16.
(e), Quantitatively analysis p-Akt in ‘‘d’’ by densitometry assay.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 5414 | DOI: 10.1038/srep05414 7Figure 6 | Stable knockdown of endogenous ME2 levels in A549 cells suppresses tumor formation. (a), A549 cells transfected with ME2 of control
shRNA were injected in nude mice separately. Tumor-bearing mice were sacrificed after 6 weeks and the tumors were dissected and weighed. (b), ME2
expression levels from tumor samples (a) were analyzed by Western blotting. The full-length blots are presented in Supplemental Figure S17. (c), A549
cells containing DOX inducible-ME2 specific shRNA or control shRNA cells were subcutaneously implanted into female athymic nude mice. 10 days
later, Dox (2 mg/ml) were fed and tumor-bearing mice were sacrificed after 6 weeks and the tumors volume were measured. The tumor volume was
calculate using the formula: V 5 0.4AB
2 (A: Long diameter; B: short diameter). (d), ME2 expression levels from tumor samples (d) were analyzed by
Western blotting. The full-length blots are presented in Supplemental Figure S18. (e), Depletion of ME2 renders cells more sensitive to cisplatin
treatment. Cells in experiments without cisplatin treatment were normalized to 1 and the cells treated with cisplatin were compared to its control. (f),
StableknockdownofME2combinedwithcisplatintreatmentinA549cellssynergisticallyinhibitstumorsizeinnudemice.ME2deficientcellsfromME2
specific shRNA or control pLKO cells were subcutaneously implanted into female athymic nude mice. Tumor size was measured and calculated. (g),
Depletion of ME2 inhibits mucin-1 and vimentin expression and increase differentiation marker E-cadherin and ZO-1 expression in vivo.
www.nature.com/scientificreports
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thecontrary,supplementationbyexogenouspyruvatecanrescuecell
death to control levels (Figure 1k). These data indicate that pyruvate
production from the action of ME2 is important for cell survival/
growth.
Inordertoobtainenergyandessentialprecursorsforthesynthesis
of macromolecules, tumor mitochondria adapt by overexpressing
glutaminase to facilitate the use of glutamate as a fuel. As noted
above, high levels of ME2 in tumor cells can enable pyruvate to be
producedfrommalatewithinthemitochondriatosupplementKrebs
cycleactivity
14,19andtherebyATPproduction.Indeed,ME2isoneof
the few progression-linked enzymes in Morris hepatomas
14,a si sa
phosphate-dependentglutaminase
29,suggestinganimportantroleof
ME2 in glutamine metabolism in tumors
19. Asparate production
from oxaloacetate may be reduced because pyruvate production
from malate is compromised by ME2 knockdown. Since aspartate
is a precursor in pyrimidine biosynthesis, depletion of ME2 can also
block the synthesis of cellular building blocks.
Our data indicates that knockdown ME2 inhibits ATP, PC (fatty
acyl chain), and protein (as evidenced by decreased Val consump-
tion) biosynthesis, which may also explain some of the effects on cell
proliferation. This effect on PC appears to be greater with glucose
than with Gln as tracer (Figures 1l and 1m). These effects could be
mediated via the inhibition of the anaplerotic input from glucose-
derived pyruvate into the Krebs cycle via pyruvate carboxylation.
This may in part account for the sensitivity of ME2 knockdown to
glucose deprivation. Such switch from glutamine to glucose utiliza-
tion in ME2 knockdown cells reflects the ability of cancer cells to
reprogram their metabolism under stress. However, whether deple-
tion of ME2 affects normal cells metabolism is unclear. Normal lung
epithelialcellsexpressmuchlessME2ascomparedtoA549cells,and
knockdownofME2innormalcellsonlyslightlyincreased celldeath,
which suggests that ME2 plays a more important role in cell survival
in tumor cells than in normal cells.
A549 cells bear a point activating mutation in K-RAS
30. RAS in
turn can activate AKT via a multistep process involving both mem-
brane translocation and phosphorylation. ME2 knockdown dramat-
icallyinhibitsAKTactivity.Thisresultisintriguinginlightofthefact
AKTisinthecytosolwhileME2localizestomitochondria.However,
recentstudieshaveindicatedthatAKTactivationmaybemorecom-
plex than the canonical view above. In particular, AKT isoforms and
PDK1 have been localized to mitochondria
31–33. Also, cellular redox
status may contribute to AKT activation i.e. ROS produced in tumor
cells inhibits AKT activity
34,35, which is consistent with our findings.
Jiang et al
21 recently found that knockdown of ME2 induced sen-
escence via activation of p53. They found that ROS in ME2 knock-
down cells could activate AMPK, which further stabilized p53. In
their studies, depletion of ME2 induced senescence and suppressed
tumor growth, interestingly even in the p53
2/2 HCT116 xenograft
model. The mechanism for the latter remains uncertain. Our study
suggests that in ME2 knockdown cells, AKT is inhibited via two
mechanisms: modulation of PTEN and of PDK1 expression.
Exogenous DMM mimicked the ME2 knockdown phenotype in
A549 cells, increased ROS levels and caused AKT inhibition.
Scavenging ROS by NAC rescued DMM mediated AKT inhibition,
suggesting that ROS mediate AKT activation. It is worth noting that
the effect of ME2 on AKT activity may vary with cell type. In leuke-
mia cells we have previously reported that knockdown of ME2
increasesAKTactivity
15.Thiseffect,however,maybeduetoaneffect
on hemoglobin synthesis during leukemia cell differentiation and
hemoglobin synthesis might stimulate AKT
36.
In conclusion, our data indicate that ME2 plays a crucial role in
modulating lung cancer differentiation and growth. Our study also
shows that ME2 is overexpressed in a majority of solid tumors. Of
note, the p53 protein is degraded in A549 cells due to deletion of the
p14ARFlocus.BecauseARFregulatesp53bybindingtoMDM2,loss
of ARF expression results in hyperactive MDM2 and enhanced
degradation of p53
10. Decreased p53 has been shown to increase
ME2 expression, and vice versa
21 . Even if A549 cells retain some
functionalp53,theamountshouldbeverylowbecausep53proteinis
maintainedatlowsteady-statelevelseveninnormalunstressedcells.
Therefore, a decreased p53 level will increase ME2 expression. We
havealsofoundthatinhibitionofME2suppressesgrowthofmultiple
types of cells including lung cancer cells, breast cancer cells and
melanoma cells (Figure S2) via the impairment of AKT activity. To
the best of our knowledge, this is the first study showing that ME2 is
involved in the regulation of AKT signaling transduction pathway.
Collectively, our findings highlight ME2 as an attractive target for
tumor therapy in a range of tumor types, including those in which
p53 is mutated or absent.
Methods
Cell culture and infection. The human lung cancer cell line A549, H1650, normal
lung primary epithelial (NLP) cells and breast cancer cell line MCF-7 were obtained
from American Type Culture Collection (ATCC) and grown in Hams/F12 Medium
(Cellgro, VA), RPMI1640, airway epithelial cell basal medium and DMEM,
respectively. All media were supplemented with 10% (v/v) fetal calf serum, 100 units
penicillin and 100 mg/ml streptomycin, and grown at 37uC and 5% CO2. Primary
melanoma cell lines (WM983B and WM852) were purchased from Wistar Institute
and maintained in melanoma growth medium containing 80% MCDB153, 20%
Leibovitz’sL-15,2%FBS,5 mg/mlInsulinand1.68 mMCaCl2.A549,H1650,MCF-7,
WM983B, WM852 and NLP cells were transduced separately with empty shRNA
vector control and three different ME2 shRNA lentiviral particles as previously
described
15. The three ME2 shRNA sequence (sense) used in this study were (Open
Biosystem): shME2-1, 59-CGGCATATTAGTGACAGTGTT-39; shME2-2, 59-
CCCAGTATGGACACATCTT TA-39; and shME2-3, 59-GCACGGCTGAAGA-
AGCATATA-39.Briefly,A549cellstransducedwithlentiviralparticleswereselected
in puromycin (Sigma Aldrich) to generate stable cell lines encoding empty vector
shRNA or ME2 shRNA. Hereafter, we named these pools pLKO, shME2-1, shME2-2
and shME2-3, respectively. In order to generate single ME2 knockdown clone, cells
from the stable knockdown pools were seeded in a 10-cm plate at 15500 dilution.
Individual clones were selected by cloning disc. The single clone corresponding to its
parental pools were named pLKO-s, shME2-1s, shME2-2s and shME2-3s,
respectively.
Tumor lysate assay and tissue array. Human cancer tissues lysed in RIPA buffer
were purchased from Protein Biotechnologies (Protein Biotechnologies, CA) and
analyzed for ME2 and b-tubulin expression by Western blotting. The tissue micro
arrays used for this study were the human multiple organ cancer tissue micro array
(BCN961) from US Biomax, Inc. (Rockville, MD). BCN961 contains 16 types of
common organ cancer tissues with matched or unmatched cancer adjacent normal
tissue. The array format is 3 cases per type in single core per case. Rabbit anti-ME2
primary antibody(Sigma) wasusedfor ME2staining.Thetotal positive cell numbers
and intensity of anti-ME2 staining were computed and measured by ImageScope
from Aperio Scanning System.
Western blotting. A549 cells with and without ME2 knockdown treated were lysed
withRIPAbuffer(50 mMTris-HCl,pH7.4,150 mMNaCl,1%NP-40,0.1%SDSand
0.5% sodium deoxycholate), and equal amount of proteins were resolved by 4%–12%
Bis-Tris gels (Invitrogen), as previously described
15.
Proliferation, clonogenic assay and Annexin-V assay. Control and ME2 deficient
cell lines were plated in 6-well plate and counted by Coulter counter. For the
clonogenic assay, A549 with stably expression ME2 knockdown and control shRNA
cellswereseededina6-wellplateatadensityof200cellsperwell.Colonieswerefixed
with 10% formaldehyde for 5 min and stained with 0.5% crystal violet for 30 min.
Cell death was measured by staining with the Nexin reagent using a Nexin kit and
counting on the Guava PCA-96 system (Guava Technologies) as per the
manufacture’s protocol.
Determination of cellular reactive oxygen species (ROS). Intracellular ROS
production was measured by staining with CM-H2DCFDA as described earlier
15.
Xenograft model in nude mice. Animal experiments were performed under federal
guidelines and approved by the Institutional Animal Care and Use Committee
(IACUC) of the Beth Israel Deaconess Medical Center (approval number 0342007).
A549xenograftsinnudemiceweregeneratedbyfollowingthedescriptionofVerraxJ
et al.
37. Tumor-bearing mice were sacrificed after 6–8 weeks and tumor masses were
measured or imaged before excision. Tumor volume were measured and calculate
using formula V 5 0.4AB
2 (A: Long diameter; B: short diameter). ME2 in tumor
samples were analyzed by Western Blot.
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deficient cells were measured by ATP Bioluminescence Assay Kit CLS II (Roche,
Germany) according to the manufacturer’s instructions as described before
15.
Metabolite profiling. To determine differences in metabolite profiles between ME2-
depletedandcontrolcells,metaboliteextractswerepreparedandthenanalyzedusing
liquid chromatography tandem mass spectrometry (LC-MS) as described before
15.
13C-Glucose labeling and
13C metabolite isotopologue distributions analysis. Two
separate tracer experiments were performed, each with duplicate samples. For the
first experiment, A549 cells were cultured in 10 cm plates for 24 hr in Gln-minus
Hams/F12 medium (Sigma) supplemented with 0.2%
13C6-Glc (resulting in 50% of
glucose as
13C6-Glc) or 1 mM
13C5,
15N2-Gln (Sigma) and 10% dialyzed FBS (10 kDa
MWCO, Atlanta Biological). The second experiment was performed similarly with a
custom Hams/F12 medium without glucose and Gln (Cellgro, Mediatech) but
supplemented with 0.2%
13C6-Glc 1 1 mM unlabeled Gln (100% of glucose as
13C6-
Glc) or with 1 mM
13C5,
15N2-Gln 1 0.2% unlabeled Glc. Samples of the medium
samples were taken for
1H NMR analysis at 0, 3, 6, 12, and 24 h.Cell metabolism was
immediately quenched with cold acetonitrile (220uC). Both polar and lipid
metabolites were extracted in acetonitrile5H2O5chloroform (251.551, v/v) as
described previously
18,38. Metabolites were analyzed by NMR, their MTBSTFA
derivatives by gas chromatography-mass spectrometry (GC-MS), and by direct-
infusion Fourier transform-ion cyclotron resonance-MS (FT-ICR-MS) as described
previously
18,39–41.Mediummetaboliteswereextractedincold10%trichloroaceticacid
to precipitate proteins and lyophilized before MTBSTFA derivatization, followed by
1D
1H NMR analysis
17. Separate aliquots of the medium were deprived with
MTBSTFA for GC-MS. The metabolites were identified and quantified using
XCalibur software (ThermoFinnigan) for the MS data and MestReNova software
(Mestrelab Research) for the NMR data. Results from both NMR and GC-MS
measurements were normalized to the total protein weight determined by the BCA
method (Pierce).
Statistical analysis. All data are expressed as the mean 6 s.d. or SEM and were
analyzed using the two-tailed Student t-test or one-way ANOVA. P , 0.05 was
considered to be significant. *:P, 0.05; **:P, 0.01; ***:P , 0.001. All tests were
performed using the Prism software (GraphPad Software, Inc., La Jolla, CA).
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